Life Sciences

Lung Cancer Data from AbbVie Paves Way for Accelerated ...

AbbVie is actively seeking accelerated approval for its promising c-Met antibody...

Amgen Expands Amazon Partnership to Seek Generative AI ...

In a concerted effort to enhance the discovery and manufacturing processes of ph...

Roivant Bids Farewell to Lupus Treatment Following Phas...

Roivant CEO Matt Gline had never been too confident of lupus drug brepocitinib. ...

In a late-stage trial, GSK’s blood cancer medication ac...

GlaxoSmithKline (GSK) has achieved a significant breakthrough in its efforts to ...

GSK Drops Bowel Disease Asset Amid Immunology Unit Changes

GlaxoSmithKline (GSK) has jolted the pharmaceutical community with its abrupt de...

AstraZeneca’s Strategic Leap into KRAS G12D with Chines...

AstraZeneca has secured a significant deal in the competitive field of cancer re...

Novo Nordisk Set to Slash Victoza Production to Boost O...

In response to the escalating demand for its GLP-1 weight loss products, Novo No...

Merck to Purchase Caraway Therapeutics For Over $600M

Merck & Co. has openly expressed its continuous pursuit of acquisitions, and cur...

NanoString Faces Setback in Patent Infringement Case Ag...

In a recent legal skirmish in the biotechnology sector, NanoString finds itself ...

InDex’s Ulcerative Colitis Drug Experiences Failure in ...

The Swedish biotech InDex has delivered surprising news to investors, announcing...

Novo Nordisk announces €2.1 billion commitment to France

Novo Nordisk has announced a substantial investment of €2.1 billion to expand it...

Lilly plans to construct a $2.5 billion manufacturing f...

Eli Lilly, a U.S.-based pharmaceutical company, has announced plans to construct...

Setback for Bayer as Promising Anti-Clotting Drug Trial...

In a significant setback for Germany’s pharmaceutical giant Bayer, the company h...

Karuna Therapeutics Phase 1b Trial Results Reinforce Ca...

The  Phase 1b unrestricted-label, eight-week residential trial meant to assess t...

FDA Expresses Doubt Over Merck’s Cough Candidate

Merck & Co. is racing against the clock to launch the first medication for chron...

Gilead gives Arcellx $285 million to extend agreement f...

Gilead Sciences subsidiary, Kite Pharma, is allocating $285 million towards adva...